SCHEMBL3787237

SCHEMBL3787237

COc1ccc(C(=O)Nc2ccc(NC(=O)c3ccc(OC)cc3)c(Cl)c2)cc1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.68
NPC1 O15118 7/20 0.67
RAB9A P51151 7/20 0.67
SMN1; SMN2 Q16637 5/20 0.67
KMT2A Q03164 5/20 0.67
TP53 P04637 4/20 0.67
MEN1 O00255 4/20 0.67
LMNA P02545 1/20 0.67
ALOX15 P16050 1/20 0.67
F10 P00742 2/20 0.64
KDM4E B2RXH2 4/20 0.64
ALDH1A1 P00352 6/20 0.63
CHRM1 P11229 1/20 0.62
POLB P06746 1/20 0.62
TAS1R3 Q7RTX0 1/20 0.62
TAS1R1 Q7RTX1 1/20 0.62
TAS1R2 Q8TE23 1/20 0.62
CYP1A2 P05177 2/20 0.61
CYP2C9 P11712 2/20 0.61
CYP2C19 P33261 2/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5419665 0.90 F10 (0.74) MAPTNPC1RAB9ASMN1; SMN2KMT2A
SCHEMBL3781363 0.89 KDM4E (0.75) MAPTNPC1RAB9ASMN1; SMN2KMT2A
SCHEMBL5423504 0.86 MAPT (0.71) MAPTNPC1RAB9ASMN1; SMN2KMT2A
SCHEMBL6571257 0.85 PDK1 (0.68) NPC1RAB9ASMN1; SMN2TP53ALOX15
SCHEMBL6571265 0.85 PDK1 (0.68) NPC1RAB9ASMN1; SMN2TP53ALOX15
SCHEMBL10238305 0.84 KCNK9 (0.69) MAPTNPC1RAB9ASMN1; SMN2KMT2A
SCHEMBL7244178 0.83 F10 (0.73) MAPTNPC1RAB9ASMN1; SMN2KMT2A
SCHEMBL3788723 0.82 NPC1 (0.65) MAPTNPC1RAB9ASMN1; SMN2KMT2A
SCHEMBL11573279 0.82 NPC1 (0.65) MAPTNPC1RAB9ASMN1; SMN2KMT2A
SCHEMBL6785591 0.81 MAPK14 (0.74) MAPTNPC1RAB9ASMN1; SMN2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100087680-A1 METHOD FOR PRODUCING BIARYL COMPOUND SUMITOMO CHEMICAL COMPANY LIMITED (JP) 2010-04-08 US disclosed
EP-1914221-A1 PROCESS FOR PRODUCING BIARYL COMPOUND Sumitomo Chemical Company, Limited (JP) 2008-04-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100087680-A1 METHOD FOR PRODUCING BIARYL COMPOUND NISCH, BLVRB, BBOX1 MAPT 3312/4885NPC1 724/4885RAB9A 1357/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.